公开(公告)号：US20240358701A1

公开(公告)日：2024-10-31

申请号：US18688075

申请日：2022-09-01

申请人： ESSA Pharma Inc.

发明人： Peter VIRSIK

IPC分类号： A61K31/505 ,  A61K31/4166

CPC分类号： A61K31/505 ,  A61K31/4166

摘要： The present disclosure generally relates to pharmaceutical compositions and combinations comprising N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy) methyl)pyrimidin-2-yl)methanesulfonamide or a pharmaceutically acceptable salt, or solvate thereof, and a second therapeutically active agent, such as enzalutamide. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer.

公开(公告)号：US20240343707A1

公开(公告)日：2024-10-17

申请号：US18631992

申请日：2024-04-10

申请人： Southern Research Institute ,  Oregon Health & Science University

发明人： Syed Kaleem Ahmed ,  Shilpa Dutta ,  Daniel N. Streblow ,  Corinne E. Augelli-Szafran ,  Omar Moukha-Chafiq ,  Ali Nakhi ,  Ashish Kumar Pathak

IPC分类号： C07D401/12 ,  A61K31/505 ,  A61K31/506 ,  A61K31/55 ,  A61K31/675 ,  A61P31/14 ,  C07D239/26 ,  C07D403/12 ,  C07D405/12 ,  C07D513/12 ,  C07F9/6512

CPC分类号： C07D401/12 ,  A61K31/505 ,  A61K31/506 ,  A61K31/55 ,  A61K31/675 ,  A61P31/14 ,  C07D239/26 ,  C07D403/12 ,  C07D405/12 ,  C07D513/12 ,  C07F9/6512

摘要： The present disclosure is concerned with substituted phenyl ethynyl pyrimidine compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20240343694A1

公开(公告)日：2024-10-17

申请号：US18294422

申请日：2022-08-01

申请人： KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

发明人： Kwangho LEE ,  Krishna Babu DUGGIRALA ,  Gil Don CHOI ,  Chong Hak CHAE ,  Myoung Eun JUNG ,  Yujin LEE ,  Byoung Chul CHO

IPC分类号： C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D417/12

CPC分类号： C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D417/12

摘要： A pyrimidine derivative, a method for preparing the pyrimidine derivative, and a pharmaceutical composition comprising the pyrimidine derivative are disclosed. Also disclosed is a method for preventing or treating cancer which includes administering the pyrimidine derivative or a composition containing the pyrimidine derivative to a subject in need of cancer treatment or prevention. The pyrimidine derivative exhibits a high inhibitory ability against EGFR mutation and HER2 mutation, and thus can be effectively used in treatment of cancer in which EGFR mutation and HER2 mutation have occurred

公开(公告)号：US20240342171A1

公开(公告)日：2024-10-17

申请号：US18294472

申请日：2022-08-16

申请人： Nanyang Technological University

发明人： Gerhard GRÜBER ,  Roderick Wayland BATES ,  Priya RAGUNATHAN

IPC分类号： A61K31/505 ,  A61K31/498 ,  A61K45/06 ,  A61P31/00

CPC分类号： A61K31/505 ,  A61K31/498 ,  A61K45/06 ,  A61P31/00

摘要： Disclosed herein is the use of a compound of formula I, or a salt or a solvate thereof, in the treatment of a bacterial infection caused by Mycobacterium abscessus, where the compound of formula (I) has the following formula: I where: R1, Ra, R2, R3, X, Y, Z and R4 are as defined herein. Also disclosed herein are combination treatments using the compound of formula I and pharmaceutical formulations comprising said compound.

公开(公告)号：US20240327334A1

公开(公告)日：2024-10-03

申请号：US18390287

申请日：2023-12-20

申请人： Enanta Pharmaceuticals, Inc.

发明人： Xuri GAO ,  Bin WANG ,  Hui CAO ,  Jiajun ZHANG ,  Yuk Ming SIU ,  Jiang LONG ,  Wei LI ,  Matthew C. RHODES ,  Xuechao XING ,  Jianming YU ,  Scott MITCHELL ,  Yat Sun OR

IPC分类号： C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/40

CPC分类号： C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/4015

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12097199B2

公开(公告)日：2024-09-24

申请号：US17258845

申请日：2019-07-08

申请人： Takeda Pharmaceutical Company Limited

发明人： Sai Murali Krishna Pulukuri

IPC分类号： A61K31/505 ,  A61P35/02 ,  C07K16/28

CPC分类号： A61K31/505 ,  A61P35/02 ,  C07K16/2887

摘要： The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer or autoimmune disease in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxy-cyclopentyl]methyl sulfamate (Compound I-263a) or a pharmaceutically acceptable salt, in combination with one or more anti-CD20 antibodies. Also provided are medicaments for use in treating cancer or autoimmune disease.

公开(公告)号：US12083176B2

公开(公告)日：2024-09-10

申请号：US17560402

申请日：2021-12-23

申请人： Sanofi Biotechnology

发明人： Corinne Hanotin ,  Laurence Bessac ,  Umesh Chaudhari

IPC分类号： C07K16/40 ,  A61K39/395 ,  A61P3/06 ,  A61J1/05 ,  A61K31/215 ,  A61K31/366 ,  A61K31/404 ,  A61K31/435 ,  A61K31/47 ,  A61K31/505 ,  A61K39/00 ,  A61K45/06 ,  C07K14/47

CPC分类号： A61K39/3955 ,  A61P3/06 ,  C07K16/40 ,  A61J1/05 ,  A61K31/215 ,  A61K31/366 ,  A61K31/404 ,  A61K31/435 ,  A61K31/47 ,  A61K31/505 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/545 ,  A61K45/06 ,  C07K14/4703 ,  C07K2317/21 ,  C07K2317/76

摘要： The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.

公开(公告)号：US12083118B2

公开(公告)日：2024-09-10

申请号：US16982842

申请日：2019-03-29

申请人： Arbutus Biopharma Corporation

发明人： Yingzhi Bi ,  Bruce D. Dorsey ,  Yi Fan ,  Christopher Brooks Moore ,  Duyan Nguyen

IPC分类号： A61K31/506 ,  A61K31/137 ,  A61K31/277 ,  A61K31/4164 ,  A61K31/444 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/505 ,  A61K45/06 ,  C07C217/58 ,  C07C255/61 ,  C07D211/60 ,  C07D233/26 ,  C07D239/06 ,  C07D401/12 ,  C07D401/14

CPC分类号： A61K31/506 ,  A61K31/137 ,  A61K31/277 ,  A61K31/4164 ,  A61K31/444 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/505 ,  A61K45/06 ,  C07C217/58 ,  C07C255/61 ,  C07D211/60 ,  C07D233/26 ,  C07D239/06 ,  C07D401/12 ,  C07D401/14

摘要： The present invention includes substituted 3,3′bis(phenoxymethyl)-1,1′-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.

公开(公告)号：US20240270699A1

公开(公告)日：2024-08-15

申请号：US18604472

申请日：2024-03-13

申请人： Lomond Therapeutics, Inc.

发明人： Volodymyr Kysil ,  Vladislav Zenonovich Parchinsky ,  Alexei Pushechnikov ,  Alexandre Vasilievich Ivachtchenko ,  Nikolay Savchuk

IPC分类号： C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  A61K31/55 ,  A61K31/5513 ,  C07D239/50 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D409/14 ,  C07D411/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

CPC分类号： C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  A61K31/55 ,  A61K31/5513 ,  C07D239/50 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D409/14 ,  C07D411/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

摘要： The present invention is generally directed to inhibitors of hematopoietic progenitor kinase 1 (HPK1), leucine rich repeat kinase 2 (LRRK2) protein, FMS-like tyrosine kinase 3 (FLT3) gene, interleukin-1 receptor-associated kinase 1 (IRAK1), interleukin-1 receptor-associated kinase 4 (IRAK4), and Janus kinases (JAKs), including Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2) useful in the treatment of diseases and disorders modulated by said HPK1, LRRK2, FLT3, IRAK1, IRAK4, and JAKs, having the Formula (I):

公开(公告)号：US20240269136A1

公开(公告)日：2024-08-15

申请号：US18540310

申请日：2023-12-14

申请人： Genentech, Inc.

发明人： Scott Andrew FOSTER ,  Xin YE

IPC分类号： A61K31/505 ,  A61K31/357 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55

CPC分类号： A61K31/505 ,  A61K31/357 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55

摘要： Provided herein are combinations comprising: (i) one or more EGFR inhibitors; and (ii) one or more PERK activators, such as the specific EGFR inhibitors and PERK activators described herein. Also provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of such combinations.